key: cord-0703188-7xj9kvmz
authors: Rojas, Manuel; Acosta-Ampudia, Yeny; M. Monsalve, Diana; Ramírez-Santana, Carolina; Anaya, Juan-Manuel
title: How important is the assessment of soluble ACE-2 in COVID-19?
date: 2020-11-06
journal: Am J Hypertens
DOI: 10.1093/ajh/hpaa178
sha: c16e79e760105a2cddf8eb46cb7eab5b896b8f66
doc_id: 703188
cord_uid: 7xj9kvmz

nan

A c c e p t e d M a n u s c r i p t Dear editor, We have read with interest the manuscript from Rieder and collaborators. 1 They showed that patients with COVID-19 did not exhibited changes in the renin-angiotensin-aldosterone system (RAAS). Interestingly, sACE-2 was unchanged in infected patients. However, they recognized that the activity of these markers in severe COVID-19 remains elusive. In addition, data about sACE-2 activity in recovered patients is unknown.

We conducted a cross-sectional study of 80 subjects to estimate the levels of sACE-2 in a group of severe but not critically ill confirmed COVID-19 patients by reverse transcriptase polymerase chain reaction (RT-PCR) and with less than 2 weeks from onset symptoms (N=23), a group of recovered patients (i.e., remission of symptoms or weaning of oxygen after 30 days) in whom two consecutive negative RT-PCR results from nasopharyngeal swabs within 48 hours were registered (N= 35), and a pre-pandemic control group (i.e., samples collected 4 years before the onset of the pandemic -N= 22). sACE-2 was measured by enzyme linked immunosorbent assay (ELISA) using the commercial kit Biovision (San Francisco, CA, USA) following the manufacturer's instructions.

In brief, the kit is a quantitative sandwich ELISA, with a detection range 0.391-25 ng/mL. Samples were 1:3 diluted. We made a linear model adjusted by sex and age to estimate the differences among groups. Correlation analysis was performed using the Spearman test for non-parametric data. This study was approved by the Institutional Review Board of the Universidad del Rosario. Written informed consent was solicited from each individual.

There was no significant difference in the levels of sACE-2 among groups ( Figure 1A and B).

Significant correlations among levels of sACE-2 and clinical parameters in severe COVID-19 patients were not observed, including viral load ( Figure 1C ). Network analysis revealed that sACE-2 was not close to other inflammatory markers ( Figure 1D ). This data suggests sACE-2 activity is unchanged in severe COVID-19 and remains unaltered in about 1 month after clinical recovery. In addition, absence of correlations advocate for a lack of value for sACE-2 A c c e p t e d M a n u s c r i p t as biomarker of COVID-19 severity. This is in line with recent evidence that did not found any effect (i.e., helpful or deleterious) of RAAS inhibitors in COVID-19. 2 In addition, there was not a correlation between sACE-2 and viral load. Recombinant sACE-2 have been recently suggested as therapeutic option for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 3 Our findings confirms that levels sACE-2 are not associated with viral load in severe patients. In conclusion, current data do not support routine use of sACE-2 in the follow-up of patients with COVID-19 and confirms that levels ACE-2 do not influence severity of disease in COVID-19.

A c c e p t e d M a n u s c r i p t

Serum ACE-2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19

COVID-19: ACE2centric Infective Disease?

Human recombinant soluble ACE2 in severe COVID-19

The authors thank all the members of the CREA and the "CP-COVID-19 Group" for contributions and fruitful discussions.

This work was supported by Universidad del Rosario (ABN-011) , Bogota, Colombia.

All individuals singed informed consent prior participation in this study.

The authors declare that they have no competing interests.A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t